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Abstract 
Introduction: The a-Klotho protein was discovered as a gene controlling the process of aging, but further studies indicated that it also plays 
the role of a tumour suppressor. Although numerous studies were performed on the role of the a-Klotho gene and protein in neoplasia, 
the data on a-Klotho protein expression in thyroid cancers are very scarce. Our study presents the immunohistochemical investigation 
of a-Klotho expression in benign and malignant thyroid tumours.
Material and methods: The material included samples of benign (nodular hyperplasia, follicular adenoma), differentiated (follicular and 
papillary) cancers and aggressive thyroid cancers of low differentiation grade. The samples were immunostained using two different 
monoclonal anti-a-Klotho antibodies.
Results: From the two antibodies used in this study, one (EPR6856) reacted probably with the soluble form of Klotho and immunostained 
mostly the colloid filling thyroid follicles and intravascular or extravascular serum deposits. The other (A-9 antibody) immunostained 
the follicular epithelium in benign thyroid lesions as well as the epithelial tumoural cells in differentiated thyroid (follicular and papil-
lary cancers). In the thyroid cancers of high malignancy, the immunostaining with A-9 anti-a-Klotho antibody was (except in one case) 
negative or very weak.
Conclusion: Our results indicate that lowered expression of a- Klotho is involved in the process of thyroid neoplasia. (Endokrynol Pol 
2019; 70 (3): 237–240)
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Introduction 
The a-Klotho protein was discovered in mice in the 
1990s as a gene coding a protein exhibiting anti-aging 
properties. It was shown that its inactivating muta-
tion leads to shortening of the lifespan and induces 
a multi-systemic syndrome resembling premature ag-
ing. The overexpression of this gene, in contrast, elon-
gated lifespan [1]. The name Klotho refers to a Greek 
mythological goddess whose role was to cut the thread 
of human life. Further studies revealed the presence 
of Klotho in humans as well as its role as a tumour 
suppressor [2, 3]. As the authors cited above indicate, 
the mechanism of anti-cancer activity of Klotho may 
depend on the inhibition of growth factors like IGF-1 
and b-FGF. The anti-aging activity of Klotho may at 
least partially be similar since the bulk of evidence 
indicates a role of IGF-1 overexpression in aging [for 
review see: 4]. Other pathways in anti-cancer effects of 
Klotho were also taken into consideration [for review 
see: 5, 6]. Although a wide range of human cancers were 
investigated for the expression of a-Klotho, we found 
only one paper dealing with thyroid cancer [7]. In the 
above-mentioned paper it was shown that the overex-
pression of Klotho induces the inhibition of growth and 
increases apoptosis in follicular thyroid cancer cell lines 
in vitro. Moreover, in contrast to the numerous studies 
on a-Klotho expression done by means of molecular 
biology techniques, immunohistochemical studies were 
very scarce, as well in cancers as in normal tissues [8, 
9]. The present paper reports the immunohistochemi-
cal investigation of a-Klotho in benign thyroid lesions 
and thyroid cancers. 
Material and methods
Tissue samples
The project was approved by the Bioethical Committee of the 
Medical University of Lodz, number RNN/79/17/KE. The study 
materials comprised 53 (aged 23–89 years) archived thyroid tis-
sues from 10 men (36–77; mean age: 59.6 years) and 43 women 
(23–89, mean age: 54.9 years). The investigated group consisted 
of 17 benign thyroid neoplasms (nodular goitres and follicular 
adenomas), 11 papillary cancers, 13 follicular cancers, and 12 ma-
lignant thyroid tumours (five poorly differentiated and seven 
anaplastic tumours). 
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staining in the blood vessels was negative. No positive 
immunostaining was found in the aggressive thyroid 
cancer tissues (PDTC and ATC). Two of the PDTC 
samples exhibited a-Klotho immunopositivity inside the 
intravascular serum deposit but not vessel walls and in 
the inflammatory infiltration. Weak immunoreaction was 
observed in the single stromal cells of one PDTC sample. 
Immunostaining with A-9 antibody
In the benign lesions (nodular hyperplasia or follicular 
adenoma) in all the samples a strong positive immu-
nostaining in the vast majority of follicular epithelia 
was observed (Fig. 3). In contrast to EPR antibody, the 
immunostaining of colloid is very rare (present in a few 
follicles in only one case of nodular hyperplasia). No im-
munoreaction was observed in blood vessel content. In 
differentiated thyroid cancers (papillary and follicular 
cancers) we found strong immunostaining of tumoural 
cells in all but one sample (Fig. 4 and 5). In one case 
(follicular cancer) the immunoreaction was negative 
except a few strongly positive follicles. In poorly differ-
entiated or anaplastic cancers the immunoreaction with 
anti-a-Klotho A-9 antibody was negative or very weak 
(Fig. 6), except in one case in which it was moderate.
Discussion
In our study we used two different anti-a-Klotho 
monoclonal antibodies, with clearly distinct results. In 
the case of EPR6856 antibody the immunoreaction con-
cerns mostly the colloid filling the thyroid follicles. The 
immunoreaction is also shown in serum deposits inside 
blood vessels. Such a localisation is compatible with 
the customer’s opinion (based on the western blot 
study) that the antibody EPR6856 reacts with a soluble 
a-Klotho but not with the full length a-Klotho molecule 
Immunohistochemistry 
The tissue samples were fixed in 10% formalin and paraffin embed-
ded. All procedures as well as blocking endogenous peroxidase 
and high-temperature antigen retrieval procedure with citrate 
buffer pH 6.0 were performed. Immunohistochemical examina-
tion of a-Klotho was performed using commercially available 
monoclonal antibodies (rabbit monoclonal antibody EPR6856, cat. 
no. ab181373 from Abcam and mouse monoclonal antibody A-9, 
cat. no. sc-515942 from Santa-Cruz). All the samples were immu-
nostained with EPR6856 antibody. A-9 antibody was applied in 
24 samples (three nodular hyperplasia, three follicular adenomas, 
seven follicular cancers, two papillary cancers, and nine anaplastic 
or poorly differentiated thyroid cancers). The primary antibodies 
were applied at dilutions 1:250 (EPR6865) and 1:100 (A-9) with 4°C 
overnight incubation. After washing steps, the sections were treated 
with DAKO Real EnVision+ Detection System, Peroxidase/DAB+ 
Rabbit/Mouse (cat. no. K5007, DAKO). The immunoreaction was 
visualised with 3.3’-diaminobenzidine (DAB) solution. 
Results
Immunostaining with EPR6856 antibody
In the benign thyroid neoplasms positive immunos-
taining was observed in the follicular colloid in 7/9 
cases (Fig.  1) but not in the follicular epithelium. In 
one case a positive immunostaining was noticed in the 
intravascular serum deposit, and in other case a weak 
immunoreaction was also found in the stromal cells. In 
the follicular thyroid cancer group there was no posi-
tive immunostaining in either cancer tissues or in blood 
vessels, but positive immunoreactivity in the colloid of 
single follicles was observed. In one case of follicular 
adenoma, positive immunoreactivity in some inflamma-
tory infiltration cells and in exudate fluid was observed. 
In the papillary cancers a negative immunoreaction in 
7/11 cancer tissues with positive reaction in the colloid of 
single follicles at the periphery of the tumour was found. 
Therefore, in the two cases several immunopositive cells 
within the tumoural tissue were observed (Fig. 2). The 
Figure 1. Nodular thyroid hyperplasia. Negative immunoreaction 
with anti-a-Klotho antibody EPR6856 in follicular cells and 
positive in the colloid
Figure 2. Papillary thyroid cancer. Positive a-Klotho immuno-
staining in tumoural cells (EPR6856 antibody)
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[10]. The explanation of positive immunoreaction in 
cytoplasm of certain tumoural cells is not so simple. 
However, we have to remember that soluble a-Klotho 
sequence is included as a KL-1 fragment in the whole 
a-Klotho molecule and is expressed as the result of al-
ternative splicing but can be released also by proteolytic 
action from the full-length protein [11, 12]. When the 
A-9 antibody was used, the intensive immunostaining 
in benign thyroid lesions concerns the follicular epithe-
lium. It is in agreement with the observations of normal 
human thyroid by Lim et al. [9]. In thyroid cancers of 
low malignancy, i.e. papillary and follicular cancers, 
immunostaining with A-9 antibody occurs in almost all 
tumoural cells. In cases of highly malignant, poorly dif-
ferentiated, and anaplastic thyroid cancers (except one 
sample) the immunoreaction with A-9 anti-a-Klotho 
antibody was negative or very weak. This is compatible 
with many data showing the down-regulation of the 
a-Klotho expression in such human neoplasms as pan-
creatic [2, 13], breast [3], oral squamous cell [8], cervical 
[14], and gastric cancer [15]. Recently, it was also found 
that a protein similar to a-Klotho, namely b-Klotho, is 
decreased in the blood serum of patients with thyroid 
cancers vs. patients with benign nodular goitre [16].
The immunohistochemical examination of a-Klotho 
protein expression in thyroid samples could offer the 
possibility to differentiate between low- and high-malig-
nancy tumours. On the other hand, the immunostain-
ing of Klotho protein does not allow the differentiation 
between benign and low-malignancy cancerous lesions 
(e.g. between follicular adenomas and follicular can-
cers). These suggestions need further studies on larger 
material. To conclude, our study shows that decreased 
expression of the a-Klotho protein is involved in thyroid 
cancerogenesis in case of highly malignant cancers with 
low grade of differentiation.
Figure 6. Poorly differentiated thyroid cancer. Very weak 
immunostaining with anti-a-Klotho A-9 antibody in tumoural cells
Figure 3. Thyroid nodular hyperplasia. Strong immunostaining 
with anti-a-Klotho A-9 antibody in follicular epithelial cells
Figure 4. Follicular thyroid cancer. Strong immunostaining with 
anti-a-Klotho A-9 antibody in follicular epithelial cells
Figure 5. Papillary thyroid cancer. Strong immunostaining with 
anti-a-Klotho A-9 antibody in tumoural cells
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